Tesamorelin
Stocked in 10mg, 20mg at MontanaPep in Great Falls, Montana. Sold for laboratory research use only.
| Size | Catalog no. | Price per vial |
|---|---|---|
| 10mg | TSM10 | $45 |
| 20mg | TSM20 | $75 |
Classification
Synthetic GHRH(1-44) analogue, FDA-approved medicine
Structure and chemistry
Tesamorelin is the full 44-amino-acid sequence of human growth-hormone-releasing hormone, GHRH(1-44), carrying a single N-terminal modification: a trans-3-hexenoic acid group conjugated to the alpha-amine of the tyrosine at position 1. This hexenoyl cap sterically blocks dipeptidyl peptidase-IV (DPP-4), the enzyme that otherwise cleaves native GHRH within minutes.
What the published research shows
Tesamorelin has a substantial published clinical-trial record, anchored by two large, multicenter, placebo-controlled Phase 3 trials (a combined 806 HIV-infected adults with excess abdominal fat) with 26-week randomized phases and 26-week safety extensions, plus a large body of subsequent mechanistic, metabolic, and post-marketing research.
Mechanism of action
A GHRH-receptor agonist that stimulates pulsatile release of endogenous growth hormone from the pituitary, which in turn raises IGF-1 and shifts adipose metabolism, most notably reducing visceral adipose tissue.
Development history
Developed by Theratechnologies (Montreal, Canada) under the code name TH9507, building on the GHRH(1-44) structure characterized in the 1980s. The development program specifically targeted HIV-associated lipodystrophy, in which antiretroviral therapy is associated with excess visceral fat accumulation.
Current regulatory status
Tesamorelin is FDA-approved (brand name Egrifta, later reformulated as Egrifta SV and Egrifta WR) specifically for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Theratechnologies withdrew its European marketing application in 2012 over insufficient long-term safety data, so tesamorelin is not approved in the EU. Catalog material sold as Tesamorelin is a distinct research-grade item and should be verified analytically rather than assumed equivalent to the approved drug product.
Analytical testing
Identity and purity should be evaluated with methods appropriate to the claimed material, such as HPLC and mass spectrometry. HPLC area percentage alone does not establish molecular identity or net peptide content.
Ordering from Great Falls
MontanaPep, also known as Montana Peptides, is an independently owned supplier based at 715 13th Ave S, Great Falls, Montana. Local pickup is available by arrangement, and we ship to research addresses across Montana including Billings, Missoula, Bozeman, Helena, Butte, Kalispell and Havre. Call (406) 799-0812 or email customerservice@montanapep.com.